(Q50572020)

15 March 2018

title

Preventing relapse of major depression during interferon-alpha therapy for hepatitis C--A pilot study. (English)

1 reference

15 March 2018

author name string

Ondria C Gleason

1

1 reference

15 March 2018

John C Fucci

2

1 reference

15 March 2018

William R Yates

3

1 reference

15 March 2018

Michelle A Philipsen

4

1 reference

15 March 2018

publication date

12 April 2007

1 reference

15 March 2018

Digestive Diseases and Sciences

published in

1 reference

15 March 2018

volume

52

1 reference

15 March 2018

issue

10

1 reference

15 March 2018

page(s)

2557-2563

1 reference

15 March 2018

https://scigraph.springernature.com/pub.10.1007/s10620-006-9729-5

exact match

0 references

cites work

An open-label trial of citalopram for major depression in patients with hepatitis C.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10620-006-9729-5

Major depressive disorder in hepatitis C: an open-label trial of escitalopram

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10620-006-9729-5

A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.

21 January 2018

1 reference

12 December 2020

Retinopathy associated with high-dose interferon alfa-2b therapy

1 reference

12 December 2020

Hepatitis C, interferon alfa, and depression

1 reference

12 December 2020

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

1 reference

12 December 2020

Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.

1 reference

12 December 2020

Successful treatment of interferon alfa-induced mood disorder with nortriptyline

1 reference

12 December 2020

The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10

1 reference

12 December 2020

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

12 December 2020

Sertraline treatment of interferon-alfa-induced depressive disorder

1 reference

12 December 2020

Safety of the Treatment of Interferon-Alpha-Induced Depression

1 reference

12 December 2020

1 reference

12 December 2020

Psychiatric disorders among veterans with hepatitis C infection

1 reference

12 December 2020

Sertraline- and mirtazapine-induced severe neutropenia

1 reference

12 December 2020

Five cases of interferon-alpha-induced depression treated with antidepressant therapy

1 reference

12 December 2020

Nefazodone (Serzone) withdrawn because of hepatotoxicity.

1 reference

12 December 2020

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

12 December 2020

Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C.

1 reference

12 December 2020

Fluoxetine treatment of depression caused by interferon-alpha.

1 reference

12 December 2020

Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients

1 reference

12 December 2020

10.1007/S10620-006-9729-5

Identifiers

DOI

1 reference

15 March 2018

1 reference

15 March 2018